Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04155918




Registration number
NCT04155918
Ethics application status
Date submitted
25/10/2019
Date registered
7/11/2019
Date last updated
19/11/2020

Titles & IDs
Public title
Phase 2a Study of AR882 Alone and in Combination With Febuxostat or Allopurinol in Gout Patients
Scientific title
A Phase 2a, Open-Label Study to Evaluate the Safety and Efficacy of AR882 Administered Alone or in Combination With Febuxostat or Allopurinol in Gout Patients
Secondary ID [1] 0 0
AR882-201
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Gout Patients 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Group 1: AR882 Alone and in Combination with Febuxostat (FBX)
Treatment: Drugs - Group 2: AR882 Alone and in Combination with Allopurinol (ALLO)

Experimental: AR882/FBX -

Experimental: AR882/ALLO -


Treatment: Drugs: Group 1: AR882 Alone and in Combination with Febuxostat (FBX)
AR882 + Febuxostat, AR882 alone, Febuxostat alone

Treatment: Drugs: Group 2: AR882 Alone and in Combination with Allopurinol (ALLO)
AR882 + Allopurinol, AR882 alone, Allopurinol alone
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
PD profile of AR882 administered alone or in combination with febuxostat
Timepoint [1] 0 0
22 Days
Primary outcome [2] 0 0
PD profile of AR882 administered alone or in combination with allopurinol
Timepoint [2] 0 0
22 Days
Primary outcome [3] 0 0
Serum uric acid (sUA) response rate
Timepoint [3] 0 0
22 Days
Secondary outcome [1] 0 0
Area under the curve (AUC) for plasma AR882
Timepoint [1] 0 0
22 Days
Secondary outcome [2] 0 0
Time to maximum plasma concentration (Tmax) for AR882
Timepoint [2] 0 0
22 Days
Secondary outcome [3] 0 0
Maximum plasma concentration (Cmax) for AR882
Timepoint [3] 0 0
22 Days
Secondary outcome [4] 0 0
Apparent terminal half-life (t1/2) for AR882
Timepoint [4] 0 0
22 Days
Secondary outcome [5] 0 0
Amount excreted (Ae) into urine for AR882
Timepoint [5] 0 0
22 Days
Secondary outcome [6] 0 0
Renal clearance (CLr) for AR882
Timepoint [6] 0 0
22 Days
Secondary outcome [7] 0 0
AUC for plasma for febuxostat
Timepoint [7] 0 0
22 Days
Secondary outcome [8] 0 0
Tmax for febuxostat
Timepoint [8] 0 0
22 Days
Secondary outcome [9] 0 0
Cmax for febuxostat
Timepoint [9] 0 0
22 Days
Secondary outcome [10] 0 0
t1/2 for febuxostat
Timepoint [10] 0 0
22 Days
Secondary outcome [11] 0 0
AUC for plasma allopurinol/oxypurinol
Timepoint [11] 0 0
22 Days
Secondary outcome [12] 0 0
Tmax for allopurinol/oxypurinol
Timepoint [12] 0 0
22 Days
Secondary outcome [13] 0 0
Cmax for allopurinol/oxypurinol
Timepoint [13] 0 0
22 Days
Secondary outcome [14] 0 0
t1/2 for for allopurinol/oxypurinol
Timepoint [14] 0 0
22 Days
Secondary outcome [15] 0 0
Ae in urine for allopurinol/oxypurinol
Timepoint [15] 0 0
22 Days
Secondary outcome [16] 0 0
CLr for allopurinol/oxypurinol
Timepoint [16] 0 0
22 Days
Secondary outcome [17] 0 0
AUC for plasma for colchicine
Timepoint [17] 0 0
22 Days
Secondary outcome [18] 0 0
Tmax for colchicine
Timepoint [18] 0 0
22 Days
Secondary outcome [19] 0 0
Cmax for colchicine
Timepoint [19] 0 0
22 Days
Secondary outcome [20] 0 0
t1/2 for for colchicine
Timepoint [20] 0 0
22 Days
Secondary outcome [21] 0 0
Incidence of Adverse Events, changes in laboratory, electrocardiogram, and vital signs
Timepoint [21] 0 0
28 Days

Eligibility
Key inclusion criteria
Key

* History of gout
* sUA > 7 mg/dL
* Estimated Glomerular Filtration Rate (eGFR) = 60 mL/min/1.73m2

Key
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Malignancy within 5 years, except for successfully treated basal or squamous cell carcinoma of the skin
* History of cardiac abnormalities
* Active peptic ulcer disease or active liver disease
* History of kidney stones
* Allergy or intolerance to colchicine, febuxostat, and allopurinol

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
3/02/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
3/09/2020
Sample size
Target
Accrual to date
Final
30
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
New Zealand
State/province [1] 0 0
Christchurch

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Arthrosi Therapeutics
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The study is designed to evaluate the PK/PD, safety and tolerability of AR882 alone or in combination with febuxostat or allopurinol when administered to gout patients.
Trial website
https://clinicaltrials.gov/study/NCT04155918
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Christopher Wynne, MBChB, Grad Dip Pharm Med
Address 0 0
Christchurch Clinical Studies Trust Ltd
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT04155918